Please login to the form below

insulin glargine

This page shows the latest insulin glargine news and features for those working in and with pharma, biotech and healthcare.

Sanofi’s new CEO cuts first deal, adding Synthorx for $2.5bn

Sanofi has had a challenging few years following the loss of patent protection for its former diabetes cash cow Lantus (insulin glargine), with some pipeline successes – notably atopic dermatitis and asthma

Latest news

Sanofi said to be looking at options for $30bn consumer health unit

Sanofi has had a difficult few years following the loss of patent protection for its former diabetes cash cow Lantus (insulin glargine), with some pipeline successes – notably atopic dermatitis and asthma
Sanofi reveals positive phase 3 results for long-acting insulin Toujeo

Hopes new product can offset continuing decline in franchise. French-drugmaker Sanofi has revealed positive results for its long-acting insulin Toujeo (insulin glargine 300 units/mL), in a study which ... has compared it to Lantus (insulin glargine 100
Sanofi exits Zynquista alliance with Lexicon

The Sanofi/Lexicon partnered drug for type 1 diabetes was being co-developed as an add-on therapy to insulin injections to help improve blood sugar control. ... Zynquista was a key element in Sanofi’s plans to rebuild its diabetes franchise following
Pricing pressures peg back Lilly’s growth products

The only drug to beat analyst forecasts in the quarter was Basaglar – a biosimilar of Sanofi’s Lantus (insulin glargine) – which grew 51% to $251m.
Success for AZ, setback for Sanofi in type 1 diabetes

The decision is a blow to Sanofi’s hopes of rebuilding a diabetes franchise that has been hit the loss of patent protection for big-selling basal insulin Lantus (insulin glargine), ... Analysts have suggested that an oral drug approved as an insulin add

More from news
Approximately 22 fully matching, plus 123 partially matching documents found.

Latest Intelligence

20 for 2020 – Five pharma leaders to watch in 2020

protection for Lantus (insulin glargine) – as well as cardiovascular disease research.
Deal Watch October 2018

agreement for the development and commercialisation of a follow‐on insulin glargine product to Sanofi’s Lantus.
Mylan sees the UK paving the way for an insulin game changer

As biosimilars surge into the insulin market, governments are urged to seize ‘the opportunity of the century’. ... Mylan, the global healthcare company, has chosen the UK for the launch pad of its much-anticipated biosimilar version of the Sanofi
Going the distance

In fact, its last really big launch was some 14 years ago in the shape of Lantus (insulin glargine), the diabetes blockbuster that is now Sanofi's biggest-selling product. ... Following hot on the heels of Afrezza has been Toujeo (insulin glargine), the
Pharma deals during February 2013

Biosimilars continue to attract. Mylan's third Indian deal is in biosimilars, as it sets up an exclusive strategic collaboration with Biocon for three insulin biosimilars: Biocon's Glargine (the generic ... This deal together with the recent option

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

Sanofi promotes diabetes expert Paul Chew to chief medical officer

position. During his time at Sanofi, Dr Chew has been heavily involved in its growing diabetes business, holding responsibility for its long-acting insulin brand Lantus (insulin glargine), and his appointment

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Senior Account Director & Associate Director - Healthcare Ad...: Highly Competitive Salary, Bonus &Benefits

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Senior Content Editor - Biotechnology: Salary TBC

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Home Working Medical Copy Writer & Senior Medical Copy Write...: Highly Competitive Salary, Bonus &Benefits

Medical Writer, Senior Medical Writer, Principal Medical Writer,...: Highly Competitive Salary, Bonus &Benefits

Client Services Director – London or Home Based – Medical Commun...: Highly Competitive Salary, Bonus &Benefits

Account Management: Competitive Salary Offered

Editor & Senior Editor - Medical Communications - Home Based: Highly Competitive Salary, Bonus &Benefits

PMHub

Add my company

Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story: How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?: The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19: The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...